CagriSema: The amylin + GLP-1 combination
Medically reviewed by: Op. Dr. Ferhat İlen, ENT – Head & Neck Surgeon · Last updated:
CagriSema combines the long-acting amylin analogue cagrilintide with semaglutide. In the REDEFINE 1 trial, an average weight reduction of approximately 20–23% was reported at 68 weeks.
Regulatory / evidence status: Investigational combination developed by Novo Nordisk, currently in Phase 3 (REDEFINE); not yet approved.
What is amylin?
Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells that signals satiety. It suppresses appetite through a central neural pathway distinct from GLP-1.
Current status
Phase 3 clinical trial data have been published, and regulatory submission processes are ongoing. Consequently, it is not currently available for routine clinical practice.
Frequently asked questions
Can cagrilintide be used on its own?
It is being evaluated as monotherapy in clinical trials, but it is not currently approved.
References
This page is for information only and does not replace diagnosis, treatment advice or a prescription. Peptide and drug assessments are made only after a physician consultation. No results are guaranteed.
Ask your physician whether it is right for you